CureMetrix vs Qure.ai

Qure.ai fits a hospital radiology department with a heavy chest X-ray and head CT load. qXR-LN (510(k), December 2023) detects nodules on adult frontal chest radiographs for radiologists, pulmonologists and ER physicians. qXR-PTX-PE triages pneumothorax and effusion (510(k), August 2023), qER prioritizes head CTs (510(k), June 2020), and qCT LN Quant (510(k), August 2024) tracks nodule volumes. TB screening carries a WHO endorsement from 2021, as the vendor states, and CE marking, and it sits outside Qure's ten FDA records. CureMetrix is for a breast imaging practice adding BAC reporting to screening mammography, and its homepage calls cmAngio the first and only FDA cleared solution that quantifies and contextualizes BAC, which is vendor wording. Neither company publishes a price, so both come by quote. A hospital with chest film and head CT volume should put Qure.ai on its evaluation list.